Bisdemethoxycurcumin Induces Cell Apoptosis and Inhibits Human Brain Glioblastoma GBM 8401/Luc2 Cell Xenograft Tumor in Subcutaneous Nude Mice In Vivo

Abstract

Bisdemethoxycurcumin (BDMC) has biological activities, including anticancer effects in vitro; however, its anticancer effects in human glioblastoma (GBM) cells have not been examined yet. This study aimed to evaluate the tumor inhibitory effect and molecular mechanism of BDMC on human GBM 8401/luc2 cells in vitro and in vivo. In vitro studies have shown that BDMC significantly reduced cell viability and induced cell apoptosis in GBM 8401/luc2 cells. Furthermore, BDMC induced apoptosis via inhibited Bcl-2 (anti-apoptotic protein) and increased Bax (pro-apoptotic proteins) and cytochrome c release in GBM 8401/luc2 cells in vitro. Then, twelve BALB/c-nude mice were xenografted with human glioblastoma GBM 8401/luc2 cancer cells subcutaneously, and the xenograft nude mice were treated without and with BDMC (30 and 60 mg/kg of BDMC treatment) every 3 days. GBM 8401/luc2 cell xenografts experiment showed that the growth of the tumors was significantly suppressed by BDMC administration at both doses based on the reduction of tumor size and weights. BDMC did not change the body weight and the H&E histopathology analysis of liver samples, indicating that BDMC did not induce systemic toxicity. Meanwhile, treatment with BDMC up-regulated the expressions of BAX and cleaved caspase-3, while it down-regulated the protein expressions of Bcl-2 and XIAP in the tumor tissues compared with the control group. This study has demonstrated that BDMC presents potent anticancer activity on the human glioblastoma GBM 8401/luc2 cell xenograft model by inducing apoptosis and inhibiting tumor cell proliferation and shows the potential for further development to the anti-GBM cancer drug.

Identification of Key Drug Targets and Molecular Mechanisms of Curcumae Rhizoma Acting on HBV-Related HCC: Weighted Correlation Network and Network Pharmacological Analyses

“…It enhances α -PD-L1 antibody-mediated immune responses against bladder cancer [ 39 ]. It induces glioblastoma cell apoptosis [ 40 ]. Besides, it could cause a decrease in HCC cell viability and an increase in apoptosis [ 41 , 42 ].…”

Curcumin and Its Analogs in Non-Small Cell Lung Cancer Treatment: Challenges and Expectations

“…BDMC comprises approximately 3% of curcuminoids and is more stable than others in vivo [ 131 ]. Recent studies have suggested that BDMC plays an antitumor role via multiple biological mechanisms or synergistic modes of action, from the suppression of cell growth, proliferation, invasion, and migration, to the induction of programmed cell death in various cancers [ 132 , 133 , 134 , 135 , 136 , 137 ].…”

GRN is a prognostic biomarker and correlated with immune infiltration in glioma: A study based on TCGA data

“…Glioblastoma (GBM) is an aggressive type of glioma associated with resistance to treatments and recurrence; patients with GBM usually have a short survival rate ( 4 ). It is responsible for 50%-60% of all brain tumors and 12%-15% of all intracranial tumors ( 5 , 6 ). About 75% of temozolomide (TMZ) treated GBM patients die within 2 years owing to recurrence, demonstrating that GBM patient survival rates remain dismally poor ( 7 ).…”